Market News & Trends
Abbott to Separate Into Two Leading Companies
Abbott recently announced it plans to separate into two publicly traded companies, one in diversified medical products, and the other in research-based pharmaceuticals. The diversified…
10/17/2011
Oncobiologics Announces Two New Agreements Worth Almost $80 Million Oncobiologics recently announced it has signed two major agreements. The first is with Parilis Biopharmaceuticals, an…
Biostar Pharmaceuticals Signs Agreement to Acquire Shaanxi Weinan Huaren
Biostar Pharmaceuticals, Inc. recently announced that its wholly owned subsidiary, Shaanxi Aoxing Pharmaceutical, Ltd., entered into a Share Transfer Agreement to acquire Shaanxi Weinan Huaren…
DNAnexus Secures $15-Million Funding Led by Google Inc. Ventures & TPG Biotech
DNAnexus, a DNA data management and analysis platform, recently announced it has secured $15 million in second-round funding, led by Google Ventures and TPG Biotech.…
Eagle Pharmaceuticals & Flamel Technologies Announce License & Development Agreement
Flamel Technologies SA and Eagle Pharmaceuticals, Inc. recently announced that the two companies have entered into a license and development agreement for a Medusa-based hydrogel…
Emisphere Reports First Interpretable Results on Second Phase III Study
On July 23, 2010, Emisphere Technologies, Inc. reported that Novartis Pharma AG and its license partner Nordic Bioscience A/S provided certain information in connection with…
GlycoMimetics, Inc. Inks Licensing Deal Worth Up to $340 Million With Pfizer
GlycoMimetics, Inc. recently announced it has entered into an exclusive worldwide licensing agreement with Pfizer Inc. for the GlycoMimetics investigational compound GMI-1070. GMI-1070 is a…
Oncobiologics Announces Two New Agreements Worth Almost $80 Million
Oncobiologics recently announced it has signed two major agreements. The first is with Parilis Biopharmaceuticals, an early stage biotech company, and involves worldwide licensing for…
Puma Biotechnology Announces Licensing Agreement With Pfizer
Puma Biotechnology, Inc., a development-stage biopharmaceutical company, recently announced an agreement with Pfizer to license the worldwide commercial rights to neratinib, a potent, irreversible tyrosine…
Unilife Wins Supply Contract With Nation's Largest Healthcare Alliance
Unilife Corporation recently announced it has been awarded a 2-year contract by Premier Purchasing Partners, L.P., the group purchasing enterprise of the Premier healthcare alliance,…
Zosano Pharma & Asahi Kasei Pharma Enter Agreement for Transdermal Patch for Up to $132.5 Million
Zosano Pharma, Inc. and Asahi Kasei Pharma Corporation (AKP) recently announced they have entered into a long-term strategic collaboration for the development, commercialization, and supply…
10/11/2011
Carticept Medical Receives 510(k) Clearance for Navigator Delivery System Carticept Medical, Inc., a developer of innovative products for the treatment of cartilage injuries and osteoarthritis,…
Carticept Medical Receives 510(k) Clearance for Navigator Delivery System
Carticept Medical, Inc., a developer of innovative products for the treatment of cartilage injuries and osteoarthritis, recently announced it has received clearance from the FDA…
Intellect Neurosciences & ViroPharma Announce $126.5-Million Global Licensing Agreement
Intellect Neurosciences, Inc. recently announced that it has granted an exclusive license to ViroPharma Incorporated regarding certain of Intellect's licensed patents and patent applications related…
Particle Sciences Granted Patent on Self-Sterilizing Medical Devices
Particle Sciences Inc. (PSI), a leading pharmaceutical CRO, has received Notice of Allowance for a method of sterilizing medical devices. The patent covers the notion…
10/4/2011
Talon Therapeutics' NDA Accepted for Filing by US FDA Under Subpart H Talon Therapeutics, Inc. recently announced its NDA seeking accelerated approval of Marqibo (vincristine…
Boehringer Ingelheim Expands its Business With Biosimilars
As part of its corporate strategy, Boehringer Ingelheim recently announced it will establish a new separate business for the development and commercialization of its own…
CoreRx Adds Additional Capabilities With New Tablet Press
CoreRx, a leader in early drug contract development, has expanded manufacturing capabilities to include the OYSTAR Manesty FLEXITAB, a fully automated, single station tablet press…
Novozymes to Supply Recombumin for Type 2 Diabetes Drug
Novozymes to Supply Recombumin for Type 2 Diabetes Drug Novozymes Biopharma, part of Novozymes A/S, recently announced it has concluded an exclusive supply agreement with…
Silence Therapeutics Signs siRNA Delivery Collaboration
Silence Therapeutics plc, a leading RNA interference (RNAi) therapeutics company, recently announced it has entered into an agreement with one of the world's leading global…
